$EXEL ..Announces Positive Results frm Ph.3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib. NDA at end of year in 2014. http://t.co/ZpYv4V9Mcz
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.